ACE2 and COVID-19: Considering the relatively high expression levels of ACE2 and TMPRSS2 in cardiomyocytes, it should come as no surprise that a significant proportion of the COVID‐19 mortality is associated with cardiovascular disease (CVD), in which morbidity and mortality rates can increase in individuals with a history of cardiovascular (CV) co‐morbidities.4